Cognitive impairment and cerebral hypoperfusion in a CADASIL patient improved during administration of lomerizine
| Autor: | Masanori Nakagawa, Takahiko Tokuda, Toshiki Mizuno, Eizo Sugimoto, Akiko Hosomi, Yoshinari Nagakane, Aiko Tamura, Hideyuki Koizumi, Masaki Kondo, Yo Ushijima, Reina Isayama, Noriko Ishigami, Masahiro Itsukage |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
CADASIL Piperazines Leukoencephalopathy Dopamine Uptake Inhibitors Internal medicine Iodine Isotopes medicine Humans Pharmacology (medical) Cognitive decline Pharmacology Cerebral Cortex Tomography Emission-Computed Single-Photon Lomerizine Middle Aged medicine.disease Calcium Channel Blockers Amphetamine medicine.anatomical_structure Diffusion Magnetic Resonance Imaging Cerebral blood flow Cerebral cortex Cardiology Female Neurology (clinical) Acetazolamide Psychology Cognition Disorders Perfusion Neuroscience medicine.drug Tomography Emission-Computed |
| Zdroj: | Clinical neuropharmacology. 32(2) |
| ISSN: | 1537-162X |
| Popis: | A 64-year-old woman was admitted to our hospital for recurrent stroke and cognitive impairment and was diagnosed with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Iodine-123 iodoamphetamine single photon emission computed tomography showed hypoperfusion in the whole brain, but cerebral blood flow increased dramatically after the administration of acetazolamide in the cerebral cortex. Lomerizine, a diphenylmethylpiperazine Ca2+ channel blocker, can selectively increase cerebral blood flow. Cognitive decline and cerebral hypoperfusion improved during 2-year administration of lomerizine in this CADASIL patient, and thus, lomerizine is a potential candidate for treating cognitive impairment in CADASIL patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|